Showing 2261-2270 of 2527 results for "".
- Ribomic Announces First Injection in the Phase 2 Clinical Trial of RBM-007 (TOFU Study) in Subjects with Wet AMDhttps://modernod.com/news/ribomic-announces-first-injection-in-the-phase-2-clinical-trial-of-rbm-007-tofu-study-in-subjects-with-wet-amd/2477304/Ribomic announced that first patient has received injection in the phase 2 trial of RBM-007 for the treatment of wet age-related macular degeneration (AMD) in the United States. The first site started enrollment at the end of December 2019 and five sites are now active across the United States.</
- Fifteenth Annual Eyes on Capitol Hill Advocacy Eventhttps://modernod.com/news/fifteenth-annual-eyes-on-capitol-hill-advocacy-event/2477302/Prevent Blindness will be holding its 15th annual “Eyes on Capitol Hill” advocacy day on February 26, 2020, in Washington, D.C. The annual program provides those from across the United States the opportunity to meet with Congressional and Senate members, and their staff, to discuss vision issues
- Santen Forges Ophthalmology Partnerships With Verily and WHOhttps://modernod.com/news/santen-forges-ophthalmology-partnerships-with-verily-and-who/2477300/Santen has forged two separate partnerships with Google’s life sciences sister company Verily and the International Telecommunication Union (ITU), whose initiative is supported by the World Health Organisation (WHO), according to a
- Artificial Iris From HumanOptics Now Reimburseable Medical Producthttps://modernod.com/news/artificial-iris-from-humanoptics-now-reimburseable-medical-product/2477301/HumanOptics AG has received health insurance approval for its artificial iris Customflex ArtificialIris in the United States. Approval by the state Centers for Medicare and Medicaid Services (CMS) as a reimbursable me
- LumiThera to Expand Research into Diabetic Retinopathy for Valeda Light Delivery Systemhttps://modernod.com/news/lumithera-to-expand-research-into-diabetic-retinopathy-for-valeda-light-delivery-system/2477299/LumiThera announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in diabetic retinopathy (DR). “Recent research in our labs in both preclinical and clinical areas hav
- Alcon Receives FDA Approval for OTC Pataday Once Daily Relief for Allergy Reliefhttps://modernod.com/news/alcon-receives-fda-approval-for-otc-pataday-once-daily-relief-for-allergy-relief/2477298/Alcon announced that Pataday Once Daily Relief (olopatadine hydrochloride ophthalmic solution 0.2%) and Pataday Twice Daily Relief (olopatadine hydrochloride ophthalmic solution 0.1%) have been approved by the FDA for sale over-the-counter (OTC) in the United States. The Pataday brand features th
- Gyroscope Therapeutics Strengthens Senior Leadership Ahead of Next Stage of Company Growthhttps://modernod.com/news/gyroscope-therapeutics-strengthens-senior-leadership-ahead-of-next-stage-of-company-growth/2477297/Gyroscope Therapeutics announced the strengthening of its leadership team with the hiring of Nadia Waheed, MD, MPH, from Tufts University School of Medicine in Boston as Chief Medical Officer (CMO), and the promotion of Jane Hughes, PhD, formerly VP Translational Research, to Chief Scientific Off
- Marinosolv Technology Successfully Used in Preclinical Study of Neurotrophic Keratopathyhttps://modernod.com/news/marinosolv-technology-successfully-used-in-preclinical-study-of-neurotrophic-keratopathy/2477279/Marinomed Biotech, a globally active biopharmaceutical company with headquarters in Vienna, and the renowned University of Utah have published scientific investigations that provide initial evidence for further significant benefits of the innovative Marinosolv platform in the field of corneal eye
- Lineage Provides Positive Update on Phase 1/2a Clinical Study of OpRegen for the Treatment of Dry Age-Related Macular Degenerationhttps://modernod.com/news/lineage-provides-positive-update-on-phase-i-iia-clinical-study-of-opregen-for-the-treatment-of-dry-age-related-macular-degeneration/2477278/Lineage Cell Therapeutics a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, today provided an update from its ongoing phase 1/2a clinical study of OpRegen, the company’s retinal pigment epithelium (RPE) transplant therapy, for the treatment of dry
- Kala Pharmaceuticals Completes of Enrollment of STRIDE 3 Trial for Eysuvis for Dry Eye Diseasehttps://modernod.com/news/kala-pharmaceuticals-announces-completion-of-enrollment-of-stride-3-trial-for-eysuvis-for-dry-eye-disease/2477232/Kala Pharmaceuticals announced that it has completed enrollment in its STRIDE 3 (STRIDE – Short Term Relief In Dry Eye) phase 3 clinical trial for KPI-121 0.25%, its product candidate for the short-term treatment of dry eye disease. If approved, Kala plans to commercialize KPI-121 0.25% under the